Coronary Artery Calcium Score by Age. What Your Number Means.

A coronary artery calcium score of 200 means different things at different ages. A 48-year-old man with a CAC of 200 is at approximately the 90th percentile for his age group. The same score in a 64-year-old man may be near the 50th percentile. The number matters, but the context around the number is what drives clinical decisions.

The Mechanism

The coronary artery calcium score is a non-contrast CT scan of the chest that quantifies the amount of calcified plaque in the coronary arteries. The result is expressed as the Agatston score, a unitless number calculated from the area and density of calcified deposits across all three major coronary arteries. The test takes about 10 minutes, delivers a radiation dose roughly equivalent to a mammogram, and requires no contrast dye or intravenous access.

The calcium being measured is a marker of advanced atherosclerosis. Coronary calcification does not occur in healthy arteries. It occurs in arteries that have been through years of plaque development: monocyte infiltration, foam cell accumulation, necrotic core formation, and eventual calcification of that necrotic material. By the time a calcium deposit is large enough to register on CT, the atherosclerotic process has been underway for years to decades.

This means a CAC score is not measuring early plaque. It is measuring established plaque at a stage where calcification has already occurred. A CAC of zero does not guarantee a clean arterial system; it means no calcification has occurred yet, though early non-calcified plaque may still be present. The distinction matters most in younger patients where non-calcified, lipid-rich plaque can be biologically active and rupture-prone even before calcification develops. This is one reason CAC scanning is less useful before age 40 in most patients, and why CAC of zero in a young person with major risk factors does not fully eliminate concern.

The physical process underlying calcification reflects the body’s attempts to stabilize atherosclerotic lesions. As macrophages and foam cells die within the plaque and release their contents, apoptotic bodies and matrix vesicles accumulate calcium phosphate. Over time, these deposits mature into hydroxyapatite crystal deposits that are dense enough to appear on CT scanning. This calcification process is progressive and largely irreversible with current medical therapies. Statins can stabilize plaque and slow progression, but they do not dissolve calcium already deposited in the arterial wall. Some patients on statins actually show increased CAC scores on repeat scanning, not because their disease is worsening, but because statin therapy stabilizes and densifies the calcium already present. 5 / Solid

What the Evidence Shows

The Multi-Ethnic Study of Atherosclerosis (MESA) is the foundational dataset for CAC interpretation. MESA enrolled 6,814 adults aged 45 to 84 across six U.S. communities and tracked cardiovascular events over more than a decade. The study produced the age-sex-race percentile tables that are now used clinically to contextualize individual CAC scores, and it established the event-rate data that underlie current guideline thresholds.

The pivotal MESA finding on the prognostic significance of any detectable plaque was published in the New England Journal of Medicine in 2012 by Blaha and colleagues. A CAC score of 1 to 10 carried a hazard ratio for cardiovascular events of 3.66 compared to a score of zero. A score of 11 to 100 carried a hazard ratio of 7.73. A score above 300 carried a hazard ratio of 18.17. (Budoff et al., JACC, 2009) 5 / Solid

The zero finding is particularly important for clinical communication. A CAC score of zero in a man with intermediate 10-year cardiovascular risk by traditional calculators reclassifies him to low risk. The MESA data show that zero-score patients have an annual cardiovascular event rate of less than 1 percent over 10 years regardless of their Framingham risk score. This finding has been used to support a “statin vacation” strategy in otherwise intermediate-risk patients: if the CAC is zero, it may be reasonable to defer statin initiation and rescan in five to seven years.

The ACC/AHA 2018 guidelines on cardiovascular risk incorporated CAC as a “tie-breaker” for patients with intermediate 10-year risk (7.5 to 20 percent) where the decision to initiate statin therapy is uncertain. A CAC of zero supports deferring treatment; a CAC above 100, or above the 75th percentile for age, sex, and race, supports initiating statin therapy. (Grundy et al., Circulation, 2019) 5 / Solid

The absolute score bands from the ACC/AHA framework carry specific clinical implications. A score of zero in a man 40 to 55 with no major risk features carries a 10-year cardiovascular event rate below 1 percent by MESA data and a warranty period of approximately 5 to 7 years before repeat scanning is useful. A score of 1 to 99 establishes the presence of disease; risk factor management is indicated, and the statin discussion is appropriate. A score of 100 to 399 exceeds the threshold for statin therapy initiation in most guidelines regardless of LDL-C. A score above 400 warrants management intensity equivalent to secondary prevention, including high-intensity statin therapy, blood pressure control to below 130/80, and ApoB targeting to below 70 mg/dL. 5 / Solid

The age-specific percentile data from MESA show the ranges that define what is “expected” versus “elevated” for a given age group. For white men, median CAC scores (50th percentile) by decade are approximately: age 45 to 54, near zero; age 55 to 64, around 30; age 65 to 74, around 100; age 75 to 84, around 300. These are medians, meaning half of men in each age group are above and half below. The 75th percentile, where clinical management intensification is generally warranted, runs roughly: age 45 to 54, approximately 50; age 55 to 64, approximately 150; age 65 to 74, approximately 400. (MESA reference tables, available at mesa-nhlbi.org)

The progression rate of CAC over time provides information beyond the baseline score. Studies from MESA and other cohorts show that annual CAC progression of 15 percent or more is associated with substantially higher event rates than a stable score in the same absolute range. This is the argument for repeat scanning at 3 to 5 years in patients with established plaque: not to confirm that disease exists, but to measure how fast it is advancing.

The Rotterdam Heart Study, a long-running Dutch cohort study, provided complementary data showing that CAC scoring improved cardiovascular risk prediction significantly beyond traditional risk factors in men and women over 55. The reclassification benefit was most pronounced at the extremes: patients expected to be at moderate risk but found to have either a zero score or a score above 400 were the ones whose management was most substantially changed. (Agatston et al., JACC, 1990, for original scoring method; Rotterdam study data from Vliegenthart et al.)

Lipoprotein(a), or Lp(a), deserves specific mention in the context of CAC interpretation. Lp(a) is a genetically determined lipoprotein that carries an additional protein called apolipoprotein(a). Elevated Lp(a) accelerates coronary calcification through mechanisms involving both lipid deposition and direct endothelial damage. A man with a high CAC score for his age who has never had Lp(a) measured is missing one of the potentially reversible-in-the-future risk factors that may explain his plaque burden. Lp(a) is measured once; it does not change substantially with diet or most current medications. It matters most as an explanation for elevated CAC in the absence of traditional risk factors. 5 / Solid

CAC Scoring in Women: How Sex Differences Change Interpretation

CAC scoring in women requires specific context because the standard percentile tables and the event-rate data from MESA were derived from a mixed-sex cohort — and the CAC distribution, age-specific progression rates, and clinical thresholds for women differ meaningfully from those for men.

Lower absolute scores in women at any given age. MESA data consistently show that women have lower CAC scores than men of the same age across all age groups and ethnic groups. A 55-year-old white woman has a median CAC score near zero, while a 55-year-old white man is near a score of 30. The 75th percentile for a 55-year-old white woman is approximately 30; for a 55-year-old white man it is approximately 150. This means that any detectable CAC in a woman — a score above zero — carries different interpretive weight than the same score in a man. A CAC of 50 in a 55-year-old woman places her above the 90th percentile for her age-sex group. The same absolute score in a 55-year-old man places him near the 60th to 70th percentile. The clinical implication is that even seemingly low scores in women warrant serious discussion and management intensification. 5 / Solid

CAC zero in women is more reassuring than in men. The MESA data also show that a CAC of zero in a woman carries an excellent prognosis: 10-year event rates below 0.5 percent in most risk categories. This is more reassuring than the same zero score in a man with equivalent risk factors, because the baseline prevalence of detectable disease is lower in women at any given age, making the absence of calcification a stronger negative predictor.

The 2019 ACC/AHA prevention guidelines and women’s risk-enhancing factors. The 2019 guideline explicitly incorporates sex-specific risk-enhancing factors into the decision to obtain CAC scoring: premature menopause (before age 40), prior preeclampsia, gestational hypertension, gestational diabetes, polycystic ovary syndrome, and prior pregnancy complications. These conditions identify women at accelerated cardiovascular risk even when their standard risk score appears intermediate. For a 45-year-old woman with prior preeclampsia, borderline Pooled Cohort Equation score, and no other strong clinical indicators, a CAC scan helps resolve whether management intensification is needed. A zero score provides reassurance; any detectable score warrants risk factor optimization and monitoring.

Timing of first scan. Because women develop detectable coronary calcium approximately 10 years later than men (mean age of first detectable plaque on population-level CT is roughly 55 in women versus 45 in men), CAC scanning before age 45 in women with standard risk has lower yield. The exceptions are women with the risk-enhancing factors above (preeclampsia, early menopause) where earlier scanning provides useful information.

The perimenopause window. The perimenopausal period (typically 45 to 55) represents a cardiovascular inflection point in women: estrogen withdrawal accelerates atherogenesis, blood pressure often rises, lipids shift adversely, and insulin resistance worsens. A baseline CAC scan in a perimenopausal woman with any one of the risk-enhancing factors listed in the 2019 ACC/AHA guideline provides objective information about whether the accelerated atherosclerosis of this transition is already anatomically visible. A woman who enters perimenopause with a CAC of zero has a favorable starting point. A woman who enters perimenopause with a CAC of 60 — which would be above the 85th percentile for her age — has atherosclerosis that predated the menopause transition and needs management now, before estrogen withdrawal compounds the progression.

What to Do This Week

1. Look up your CAC score on the MESA CAC Calculator at mesa-nhlbi.org. Enter your age, sex, and race. The tool returns your age-sex-race-specific percentile. That percentile is the context your absolute score requires to be clinically meaningful.

2. If your score is at or above the 75th percentile for your age group, bring it to your physician with that framing: “My percentile is X for my age.” Request a specific conversation about ApoB target, blood pressure target, and statin therapy if not already in place.

3. If your score is zero, record the date and note the warranty concept. Plan a repeat scan at 5 to 7 years, or sooner if new risk factors emerge. A zero today is not a permanent clearance; it is a five-to-seven-year lead time before the next look is useful.

4. If you have a high CAC score and have never had Lp(a) measured, ask for it at your next blood draw. It is a single-time test that can identify a genetic driver of accelerated plaque development. It matters most for explaining unexpectedly high CAC and for risk assessment of first-degree relatives.

5. If you have had a CAC scan and have never discussed progression rate with your physician, ask whether a follow-up scan in 3 to 5 years is appropriate. The rate of change over time carries prognostic information beyond the baseline number.

The CAC score is a direct measurement of what has already happened in your arteries. It does not tell you what will happen next. What it tells you is what your arterial age is relative to your calendar age, and what preventive intensity is warranted based on the documented disease burden. The man who knows his percentile and acts on it is in a better position than the man who knows only his cholesterol.